29.75
price up icon2.37%   0.69
 
loading
Alkermes Plc stock is traded at $29.75, with a volume of 1.39M. It is up +2.37% in the last 24 hours and up +10.06% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$29.06
Open:
$29.26
24h Volume:
1.39M
Relative Volume:
0.80
Market Cap:
$4.91B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.26
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+2.41%
1M Performance:
+10.06%
6M Performance:
-15.77%
1Y Performance:
+6.29%
1-Day Range:
Value
$29.14
$29.96
1-Week Range:
Value
$28.10
$29.96
52-Week Range:
Value
$25.56
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Name
Alkermes Plc
Name
Phone
00-353-1-772-8000
Name
Address
CONNAUGHT HOUSE, DUBLIN 4
Name
Employee
1,800
Name
Twitter
@alkermes
Name
Next Earnings Date
2024-10-24
Name
Latest SEC Filings
Name
ALKS's Discussions on Twitter

Compare ALKS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
29.75 4.64B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
156.62 67.51B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.52 47.88B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.82 43.42B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.46 20.72B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.23 14.21B 2.99B 1.21B 1.13B 25.06

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-15-25 Initiated Goldman Buy
Jun-17-25 Upgrade UBS Neutral → Buy
May-28-25 Initiated Needham Buy
Mar-13-25 Initiated RBC Capital Mkts Sector Perform
Mar-04-25 Upgrade UBS Sell → Neutral
Feb-11-25 Initiated Deutsche Bank Buy
Nov-05-24 Upgrade Stifel Hold → Buy
Jun-17-24 Initiated TD Cowen Buy
Mar-19-24 Initiated Robert W. Baird Outperform
Feb-20-24 Downgrade UBS Neutral → Sell
Nov-20-23 Resumed JP Morgan Neutral
Oct-24-23 Upgrade Evercore ISI In-line → Outperform
Oct-17-23 Initiated UBS Neutral
Nov-03-22 Upgrade Piper Sandler Neutral → Overweight
Oct-14-22 Upgrade BofA Securities Underperform → Neutral
Aug-16-22 Initiated Piper Sandler Neutral
Apr-22-22 Resumed Goldman Buy
Apr-20-22 Initiated Goldman Buy
Jan-27-22 Upgrade Cantor Fitzgerald Hold → Overweight
Dec-01-21 Initiated Citigroup Neutral
Oct-07-21 Upgrade Jefferies Hold → Buy
Sep-02-21 Downgrade BofA Securities Neutral → Underperform
Oct-15-20 Upgrade Mizuho Neutral → Buy
Jul-30-20 Downgrade Goldman Neutral → Sell
Feb-14-20 Downgrade BofA/Merrill Buy → Neutral
Feb-14-20 Reiterated H.C. Wainwright Neutral
Feb-14-20 Downgrade JP Morgan Overweight → Neutral
Feb-06-20 Initiated Mizuho Neutral
Jan-31-20 Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-15-19 Upgrade Goldman Sell → Neutral
May-31-19 Initiated H.C. Wainwright Neutral
May-01-19 Downgrade Citigroup Buy → Neutral
Dec-19-18 Downgrade Goldman Neutral → Sell
Dec-14-18 Initiated Wolfe Research Underperform
Dec-13-18 Downgrade Credit Suisse Outperform → Underperform
Nov-05-18 Initiated Piper Jaffray Neutral
Aug-07-18 Initiated Stifel Hold
Jun-21-18 Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18 Initiated B. Riley FBR, Inc. Buy
May-16-18 Upgrade Citigroup Neutral → Buy
May-11-18 Initiated BofA/Merrill Buy
View All

Alkermes Plc Stock (ALKS) Latest News

pulisher
Aug 20, 2025

After culling 90% of staff, Waltham biotech finds buyer - NBC Boston

Aug 20, 2025
pulisher
Aug 20, 2025

Opioid Use Disorder Market: Generated Opportunities and Future Scope by 2032 | Indivior PLC, Alkermes, Orexo AB - openPR.com

Aug 20, 2025
pulisher
Aug 18, 2025

Chart Analysts Warn of Resistance Near Alkermes plc PriceWeekly Market Outlook & Community Driven Trade Alerts - kangso.co.kr

Aug 18, 2025
pulisher
Aug 18, 2025

Will Lowered Earnings Forecasts Shift Alkermes' (ALKS) Valuation Story or Reinforce Investor Caution? - simplywall.st

Aug 18, 2025
pulisher
Aug 17, 2025

Price Floor Holding on Alkermes plc — Rebound PossibleQuarterly Portfolio Review & Daily Profit Maximizing Trade Tips - 선데이타임즈

Aug 17, 2025
pulisher
Aug 16, 2025

Visual analytics tools that track Alkermes plc performance2025 Winners & Losers & Daily Growth Stock Investment Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Visual trend scoring systems applied to Alkermes plcJuly 2025 Update & Weekly Stock Breakout Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Intraday pattern recognizer results for Alkermes plcJuly 2025 Summary & Stock Timing and Entry Methods - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

What’s the recovery path for long term holders of Alkermes plcGap Down & Safe Entry Point Alerts - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Investors Don't See Light At End Of Alkermes Plc's (NASDAQ:ALKS) Tunnel - 富途牛牛

Aug 15, 2025
pulisher
Aug 15, 2025

Is Alkermes plc stock influenced by commodity prices2025 Trading Volume Trends & Pattern Based Trade Signal System - thegnnews.com

Aug 15, 2025
pulisher
Aug 15, 2025

Charles Schwab Investment Management Inc. Sells 21,558 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Aug 15, 2025
pulisher
Aug 15, 2025

PNC Financial Services Group Inc. Has $408,000 Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Aug 15, 2025
pulisher
Aug 14, 2025

Vanguard Group Inc. Sells 283,511 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Aug 14, 2025
pulisher
Aug 12, 2025

Live Scanner Shows Breakout on Alkermes plcMarket Surge Signal for Swing Traders Triggered - metal.it

Aug 12, 2025
pulisher
Aug 10, 2025

Is Alkermes plc in a long term uptrendWealth Leverage Stock List - mustnews.co.kr

Aug 10, 2025
pulisher
Aug 09, 2025

Avantax Advisory Services Inc. Makes New $246,000 Investment in Alkermes plc (NASDAQ:ALKS) - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

BlackRock increases stake in Alkermes to 17% - Investing.com India

Aug 08, 2025
pulisher
Aug 08, 2025

BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 07, 2025

Alkermes plc Ireland - AD HOC NEWS

Aug 07, 2025
pulisher
Aug 04, 2025

Alkermes plc Included in Top Momentum ScanInvestment Strategy Designed for Capital Protection - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

Chondrosarcoma Market: Epidemiology, Pipeline Products, - openPR.com

Aug 04, 2025
pulisher
Aug 04, 2025

Alkermes plc Announces Pricing of New Term Loans - AOL.com

Aug 04, 2025
pulisher
Aug 04, 2025

HC Wainwright Brokers Boost Earnings Estimates for Alkermes - Defense World

Aug 04, 2025
pulisher
Aug 03, 2025

What markets is AAON Inc. expanding into Is Alkermes plc stock a good long term investment optionBuild a diversified portfolio for steady growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Alkermes plc stockUnmatched market gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Alkermes plc a growth stock or a value stockInvest smarter with expert trading signals - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Alkermes plc stock price move sharplyInvest confidently with professional advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Alkermes plc stock overvalued or undervaluedGet exclusive access to expert stock recommendations - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Needham & Company LLC Reaffirms "Buy" Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Aug 03, 2025
pulisher
Aug 03, 2025

How does Alkermes plc generate profit in a changing economyBuild capital through low-risk investments - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

Aug 02, 2025
pulisher
Jul 31, 2025

Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com

Jul 31, 2025
pulisher
Jul 30, 2025

Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes stock price target raised to $42 from $40 at RBC Capital - Investing.com Nigeria

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes Beat Expectations With A Strong Second Quarter - Finimize

Jul 30, 2025
pulisher
Jul 30, 2025

Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes: Q2 Earnings Snapshot - Norwalk Hour

Jul 30, 2025
pulisher
Jul 29, 2025

Alkermes Reports Strong Q2 2025 Financial Results - TipRanks

Jul 29, 2025

Alkermes Plc Stock (ALKS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alkermes Plc Stock (ALKS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nichols Christian Todd
SVP, Chief Commercial Officer
Jun 10 '25
Sale
31.09
3,334
103,654
86,208
$17.91
price up icon 2.40%
drug_manufacturers_specialty_generic RDY
$14.51
price up icon 0.62%
$10.65
price down icon 0.37%
$135.43
price up icon 0.11%
$312.23
price up icon 0.51%
Cap:     |  Volume (24h):